Beam's base-edited cell therapy risto-cel hits primary endpoint in pivotal sickle cell trial
What's the deal? Beam Therapeutics announced on 10 November 2026 that its one-time investigational cell therapy risto-cel (ristoglogene autogetemcel, formerly BEAM-101) met the primary efficacy endpoint of the BEACON Phase 1/2 pivotal trial in sickle cell disease (SCD) patients with severe vaso-occlusive crises (VOCs) — painful blockages of blood vessels by sickled red blood cells. The trial achieved the endpoint of freedom from severe VOCs for at least 12 consecutive months, based on independently adjudicated results, and met all primary safety endpoints at the prespecified interim analysis.
How it works: risto-cel is a cell therapy made from the patient's own blood-forming stem cells, which are edited with Beam's base editing technology — a gene-editing technique that makes precise single-letter changes in DNA. The edit boosts production of fetal haemoglobin, a form of the oxygen-carrying protein that resists sickling, mimicking a naturally occurring protective condition. As of the 20 October 2026 data cutoff, 39 adults and 10 adolescents had been treated, with 31 patients completing the required follow-up period; all secondary endpoints were also met, including freedom from inpatient hospitalisation for severe VOCs for 12 consecutive months. Safety findings were consistent with the known effects of the cell-collection process, the conditioning regimen and the transplant procedure itself.
Why it matters: The results support a planned US Biologics License Application to the FDA as early as year-end 2026, which would potentially be the first approval filing for a base-edited therapy. Detailed results are expected at a medical meeting in 2027, with earlier-cutoff data to be presented at the American Society of Hematology (ASH) meeting on 12–15 December 2026 in New Orleans.
Read more: Beam Therapeutics, 10 November 2026
